Dr Graham Dark
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial | 2022 |
|
Dr Graham Dark
| Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial | 2021 |
|
Dr Graham Dark
| Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial | 2020 |
|
Dr Graham Dark
| An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor | 2019 |
|
Dr Graham Dark
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial | 2019 |
|
Dr Graham Dark
| Impact of a 2-Week Oncology Placement on Medical Students’ Perception of Cancer | 2018 |
|
Dr Graham Dark
Professor Roderick Skinner
| An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients | 2016 |
|
Dr Graham Dark
| Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma - Results of an International Expanded Access Program | 2008 |
|
Dr Graham Dark
Rebecca Perrett
| Deconstructing the construction of a learning module on practice development | 2007 |
|
Dr Graham Dark
| Developing a web-based multidisciplinary cancer education forum | 2007 |
|
Dr Graham Dark
| Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours | 2007 |
|
Dr Graham Dark
| Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP) | 2007 |
|
Dr Graham Dark
| Phase II study of vinflunine in malignant pleural mesothelioma | 2007 |
|
Dr Graham Dark
Rebecca Perrett
| Practice development - Part 1: Developing a practice initiative in oncology and palliative care | 2007 |
|
Dr Graham Dark
Rebecca Perrett
| Practice development - Part 2: evaluating a practice initiative | 2007 |
|
Dr Graham Dark
Rebecca Perrett
| Using e-learning as a tool for multidisciplinary education | 2007 |
|
Dr Graham Dark
Helen Taylor
David Talbot
| [Meeting Abstract] Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a European phase II study | 2006 |
|
Dr Graham Dark
| A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) | 2006 |
|
Dr Graham Dark
| Differentiation and definition of vascular-targeted therapies | 2005 |
|
David Talbot
Dr Graham Dark
Helen Taylor
| Interim results of the phase II study of vinflunine (VFL) in malignant pleural mesotheliorna (MPM) | 2005 |
|
Dr Graham Dark
| Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial | 2005 |
|
Dr Graham Dark
Angela Price
| Pernetrexed (P) plus carboplatin (Cb) as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC): Results of both a multi-center European and an MD Anderson Cancer Center (MDACC) phase II trials | 2005 |
|
Dr Graham Dark
| Proven bioequivalence of blood exposure between vinorelbine 80 mg/m(2) oral and 30 mg/m(2) IV doses in cancer patients. | 2005 |
|
Dr Graham Dark
| Randomized phase II parallel evaluation of OSI-211 (liposomal lurtotecan) and topotecan in women with relapsed epithelial ovarian cancer (EOC) | 2005 |
|
Dr Graham Dark
Professor Alan Calvert
| Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the national cancer institute of Canada clinical trials group | 2005 |
|
David Talbot
Dr Jane Margetts
Dr Graham Dark
Helen Taylor
| Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a phase II study | 2005 |
|
Dr Graham Dark
| Recent advances in mesothelioma | 2003 |
|
